Bissett D, Jodrell D, Harnett A N, Habeshaw T, Kaye S B, Evans D, Williams M, Canney P A
Beatson Oncology Centre, Western Infirmary, Glasgow, UK.
Br J Cancer. 1995 Jun;71(6):1279-82. doi: 10.1038/bjc.1995.247.
With the aim of increasing the dose intensity of chemotherapy in breast cancer, 14 patients with stage II-IV breast cancer were treated with FEC chemotherapy at 2 week intervals together with granulocyte colony-stimulating factor (G-CSF) 5 micrograms kg-1 s.c. on days 2-14. Five of six patients completed six courses of 5-fluorouracil 600 mg m-2, epirubicin 60 mg m-2 and cylcophosphamide 600 mg m-2 within 11 weeks. Eight patients were treated with 5-fluorouracil 700 mg m-2, epirubicin 70 mg m-2 and cyclophosphamide 700 mg m-2 and four had dose-limiting toxicity with sepsis, thrombocytopenia or mucositis. All patients who received G-CSF had satisfactory neutrophil counts by day 15 of each course. Cumulative anaemia and thrombocytopenia were observed, but treatment at the first dose was tolerable. Seven of eight patients with measurable disease had partial responses. This regimen permits a 50% increase in dose intensity compared with conventional treatment at 3 week intervals and warrants further evaluation.
为提高乳腺癌化疗的剂量强度，14例II-IV期乳腺癌患者接受了FEC化疗，每2周进行一次，并在第2 - 14天皮下注射粒细胞集落刺激因子（G-CSF）5微克/千克。6例患者中有5例在11周内完成了六个疗程的5-氟尿嘧啶600毫克/平方米、表柔比星60毫克/平方米和环磷酰胺600毫克/平方米的治疗。8例患者接受了5-氟尿嘧啶700毫克/平方米、表柔比星70毫克/平方米和环磷酰胺700毫克/平方米的治疗，其中4例出现了剂量限制性毒性，表现为败血症、血小板减少或粘膜炎。所有接受G-CSF治疗的患者在每个疗程的第15天中性粒细胞计数均令人满意。观察到有累积性贫血和血小板减少，但首次剂量的治疗是可耐受的。8例可测量疾病的患者中有7例出现部分缓解。与每3周进行一次的传统治疗相比，该方案可使剂量强度提高50%，值得进一步评估。
